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The use of a neutral peptide aptamer scaffold to anchor
BH3 peptides constitutes a viable approach to
studying their function
LKJ Stadler*,1,2,4, DC Tomlinson3,4,5, T Lee1,6, MA Knowles3 and P Ko Ferrigno1,7
The B-cell CLL/lymphoma-2 (Bcl-2) family of proteins are important regulators of the intrinsic pathway of apoptosis, and their
interactions, driven by Bcl-2 homology (BH) domains, are of great interest in cancer research. Particularly, the BH3 domain is of
clinical relevance, as it promotes apoptosis through activation of Bcl-2-associated x protein (Bax) and Bcl-2 antagonist killer
(Bak), as well as by antagonising the anti-apoptotic Bcl-2 family members. Although investigated extensively in vitro, the study of
the BH3 domain alone inside cells is more problematic because of diminished secondary structure of the unconstrained peptide
and a lack of stability. In this study, we report the successful use of a novel peptide aptamer scaffold – Stefin A quadruple mutant
– to anchor and present the BH3 domains from Bcl-2-interacting mediator of cell death (Bim), p53 upregulated modulator of
apoptosis (Puma), Bcl-2-associated death promoter (Bad) and Noxa, and demonstrate its usefulness in the study of the BH3
domains in vivo. When expressed intracellularly, anchored BH3 peptides exhibit much the same binding specificities previously
established in vitro, however, we find that, at endogenous expression levels, Bcl-2 does not bind to any of the anchored
BH3 domains tested. Nonetheless, when expressed inside cells the anchored PUMA and Bim BH3 a-helices powerfully induce
cell death in the absence of efficient targeting to the mitochondrial membrane, whereas the Noxa helix requires a membrane
insertion domain in order to kill Mcl-1-dependent myeloma cells. Finally, the binding of the Bim BH3 peptide to Bax was the only
interaction with a pro-apoptotic effector protein observed in this study.
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Programmed cell death is a tightly controlled process
encompassing a wide range of regulatory mechanisms.
Permeabilisation of the mitochondrial membrane and the
resulting release of cytochrome c into the cytoplasm is a
central event in the induction of the intrinsic apoptotic
pathway. The B-cell CLL/lymphoma-2 (Bcl-2) family of
proteins is chiefly involved in the regulation of apoptosis at
the mitochondrion.1–5 As well as apoptosis, more recent
evidence has implicated the Bcl-2 family in the regulation of
mitochondrial morphology and autophagy.6,7 Structurally, the
Bcl-2 proteins are characterised by four alpha helical Bcl-2
homology domains (BH1-4), at least one of which is present in
each family member. In functional terms, the protein family is
divided into three groups: the apoptotic effector proteins
Bcl-2-associated x protein (Bax) and Bcl-2 antagonist killer
(Bak; and possibly Bok), the anti-apoptotic proteins Bcl-2,
Bcl-2-related gene long isoform (Bcl-xl), Bcl-w, Mcl-1 and
Bcl-2-related gene A1 (A1), and finally the pro-apoptotic
BH3-only proteins. In the last group, one can further
distinguish between activators (Bcl-2-interacting mediator of
cell death (Bim) and Bcl-2-interacting domain death agonist
(Bid)) and sensitisers (e.g., p53 upregulated modulator of
apoptosis (Puma), Bcl-2-associated death promoter (Bad),
Noxa, Bcl-2-interacting killer (Bik) and more). In the event of
cytotoxic stress, Bak and/or Bax oligomerise and produce
pores in the mitochondrial outer membrane (MOM) thus
initiating MOM permeabilisation (MOMP) and cytochrome c
release.3 The mechanism of Bcl-2 family-regulated apoptosis
is predominantly described by either the direct or indirect
activation models, or a combination thereof (reviewed in
Chipuk et al.3 and Shamas-Din et al.5).
The pro-apoptotic BH3-only proteins are diverse in struc-
ture and largely unrelated except for their BH3 domain, which
represents the minimal unit of their function and is necessary
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for target protein binding and induction of apoptosis.8–11
Binding of the BH3-only Bcl-2 family members to each of their
anti-apoptotic counterparts occurs in a selective manner,
which closely correlates with their apoptotic potency.12,13 Bim,
Puma and Bid have been found to bind to all five anti-apoptotic
Bcl-2 proteins; when overexpressed in cells they potently
induce cell death. Bad and Noxa, on the other hand, bind to
complementary subsets of anti-apoptotic factors, with Bad
interacting strongly with Bcl-2, Bcl-xl and Bcl-w and Noxa
binding to Mcl-1 and A1.11,14 Overexpression of Bad
and Noxa individually failed to cause apoptosis in mouse
embryonic fibroblasts.12 Furthermore, Bim and Bid (and
maybe Puma) directly bind and activate Bax and Bak.8,15–17
As aberrant regulation of apoptosis by the Bcl-2 family often
lies at the heart of many diseases, the development of
molecular tools, which help dissect the pathways involved, is
of paramount importance. In particular, the role of the BH3
domain in isolation (i.e., outside the context of the full-length
protein) as themediator of the death signal is of significance to
clinical research, as this interaction site has become
an attractive drug target in the treatment of cancer.18,19 The
interactions of the BH3 peptides with the anti-apoptotic and
pro-apoptotic-effector Bcl-2 proteins have been studied
thoroughly in vitro, however, the BH3-only proteins are not
easily express recombinantly,12 making it difficult to derive
reliable conclusions from peptide-based interaction studies.
Moreover, introducing peptides into cells is challenging and
once inside peptides are susceptible to proteolytic degrada-
tion.20,21 Consequently, rather less emphasis has been
placed on the study of the BH3 peptides in vivo. A further
caveat to the use of the BH3 peptides in isolation is their lack
of secondary structure, which – in the absence of a structural
constraint – precludes high-affinity interactions with their
targets.16,22
We have recently reported the design and validation of a
series of new peptide aptamer scaffolds, culminating in Stefin
A quadruple mutant Tracy (SQT), derived from the mamma-
lian protease inhibitor Stefin A.23 Peptide aptamers represent
a relatively new class of alternative binding proteins, and are
defined as binding peptides constrained within a protein
scaffold.24 As binding molecules they are superior to free
peptides, which are susceptible to proteolytic cleavage in
cells, and which – because of their flexible nature – tend to
bind to protein surfaces non-specifically. In this study, we
explore the use of a novel peptide aptamer scaffold to anchor
and present four different BH3 domains as a means
of investigating their functions when expressed in cells. We
propose that such tools may in time allow a direct correlation
between biochemical and intracellular studies of BH3 helix
function.
Results
Structural analysis of the scaffold-constrained BH3
domains. Based on previous studies,12,25 26-amino-acid
stretches covering the BH3 region of Puma, Bim, Noxa
and Bad, respectively (Figure 1a), were introduced into the
N-terminal insertion site of the SQT peptide aptamer scaffold
(Figure 1b), thus creating pepPuma, pepBim, pepNoxa and
pepBad (collectively referred to as ‘pepBH3’). Circular
dichroism (CD) spectroscopy was used to assess the
secondary structure of the pepBH3 proteins (Figure 1c).
Figure 1 Structural analysis of the SQT scaffold presenting four different pro-apoptotic BH3 domains. (a) Amino-acid sequence of the four BH3 peptides used in this study.
In the Puma sequence, the underlined amino acids are deleted in pepPumaDel. (b) Nuclear magnetic resonance (NMR) structure of Stefin A (adapted from pdb ref: 1DVC).
The three sites for peptide presentation in the SQT peptide aptamer scaffold are highlighted in red. (c) The CD spectrum of SQT alone and with N-terminal insertions of the HA
tag (a negative control not expected to adopt an alpha helical configuration) or with each BH3 peptide. The single inflection point around 218 nm indicates predominantly
b-strands in the SQT and SQT-HA spectra. A shift in the inflection point to 220–222 nm, the deeper inflection of the spectrum and an additional shoulder signal the alpha helix
formed by the BH3 peptides. SQT with Noxa BH3 and the HA peptide have been reported previously23
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The empty SQT scaffold contains predominantly b-strands,
which is clearly reflected in its CD spectrum. Insertion of the
BH3 domains altered the CD spectrum in a manner that is
indicative of a-helices. When introducing the HA epitope
tag into the same insertion site, the CD spectrum of SQT
remains largely unchanged, suggesting that anchoring the
BH3 peptides within a larger open reading frame (ORF)
allows them to adopt a stable a-helical conformation.
Functional analysis of pepBH3. To study these newly
created pepBH3 proteins intracellularly, a retroviral system
(ProteoTuner) was used to stably transduce A375 melanoma
cells with the pepBH3-encoding ORFs. In this expression
system, proteins are constitutively targeted to the protea-
some until addition of a chemical stabiliser (Shield).26 To
confirm the suitability of the ProteoTuner system, expression
of SQT after addition of Shield (5 mM) at numerous
time points was examined (Figure 2a). SQT protein was
detectable after 0.5 h and increased during the time course.
Next, co-immunoprecipitation (co-IP) was used to investigate
the ability of each pepBH3 protein to interact with other Bcl-2
protein family members inside cells (Figure 2b). PepPuma
and pepBim co-IP with the anti-apoptotic proteins Bcl-xL and
Mcl-1, whereas pepBad only co-IP with Bcl-xL and pepNoxa
with Mcl-1, the latter as previously reported.23 The only
interaction detectable between a pepBH3 and a pro-
apoptotic effector protein was between pepBim and Bax.
No in vivo binding to Bak was observed. A functionally
inactive version of pepPuma (pepPumaDel), with a mutated
BH3 domain27 where three amino acids, which are crucial to
the protein–protein interaction, have been deleted
(Figure 1a) did not bind to any of the Bcl-2 family members
assayed. Surprisingly, none of the pepBH3 proteins showed
intracellular interaction with Bcl-2, which was nonetheless
present. We performed a co-IP experiment using an anti-Bad
antibody, to test whether endogenous, full-length Bad was
bound to endogenous Bcl-2 in staurosporine-treated A375
cells (Figure 2c). Although Bad successfully co-IP with Bcl-
xL, no interaction with Bcl-2 was observed, consistent with
the pepBad result (Figure 2b). In order to ascertain whether
this surprising observation was specific to A375 cells, two
separate experiments were carried out. First, Hela cells,
transfected with pepBim and the negative control pepPuma-
Del, respectively, were submitted to a co-IP experiment
(Figure 2b). Again no interaction between pepBim and
endogenous Bcl-2 was detected. Second, the binding of
endogenous full-length Bad to endogenous Bcl-2 was tested
in the non-cancerous cell line human embryonic kidney 293T
cells (Figure 2c). As for the A375 cells, an anti-Bad antibody
column was used to establish whether Bcl-2 IP with Bad in
apoptosing cells and again the result was negative.
As all the experiments so far had looked at endogenous
levels of Bcl-2, we decided to test the interaction with pepBim
when Bcl-2 was overexpressed. To that end, a mammalian
expression vector carrying Flag-tagged Bcl-2 was transiently
transfected into A375 cells carrying pepBim and pepPuma-
Del, respectively. Following transfection with Bcl-2 and
induction of peptide aptamer expression, the cells were lysed
(4 h after addition of 5 mM Shield) and co-IP carried out using
an anti-Stefin A antibody (Figure 2b, bottom panel). This time
efficient binding of pepBim to Bcl-2 could be detected, while
no interaction with pepPumaDel occurred.
Next, cleavage of PARP was monitored to test whether
pepBH3 proteins are capable of inducing apoptosis
(Figure 3a). Expression of either pepPuma or pepBim, but
not of pepBad or pepNoxa, results in efficient PARP cleavage.
This is consistent with the ability of pepPuma and pepBim to
bind to Bcl-xL and Mcl-1 (Figure 2b) and with the previously
Figure 2 PepBH3 expression and identification of their binding partners. (a) Following induction, pepBH3 expression is detectable after 30 min. (b) Co-IP of pro- and anti-
apoptotic Bcl-2 proteins with pepBH3 following their expression in A375 (top panel) and Hela cells (middle panel). There is no interaction between Bcl-2 and pepBim in A375 or
Hela cells, however, when Bcl-2 is overexpressed (in A375) binding to pepBim is significant (bottom panel, underneath dashed line). (c) IP of endogenous full-length Bad from
A375 cell lysate reveals binding of Bcl-xl, but not Bcl-2 (top panel). Equally in 293T cells, the Bad:Bcl-2 interaction does not occur (bottom panel). PARP cleavage indicates that
apoptosis was induced successfully in these cells
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reported apoptotic potential of each of the full-length
proteins.12 PARP cleavage is detectable within 30min of
induction with Shield in cells expressing pepPuma or pepBim,
and a significant decrease in the levels of the anti-apoptotic
proteins Mcl-1, Bcl-2 and Bcl-xL are observed at 4 h
(Figure 3b).
PepBim/Puma weakly localise to the mitochondria, but
strongly induce apoptosis. A cell viability assay following
induction of pepBim/Puma expression in A375 cells with
increasing amounts of Shield reveals that these peptide
aptamers efficiently cause cell death. Induction of protein
expression with 5 mM shield leads to a reduction in cell
viability by 80% (Figure 4a). PepPumaDel does not affect cell
viability (Figure 4b). To study the cellular localisation of the
peptide aptamers immunocytochemistry (ICC) was used to
probe for pepBim, pepPuma and empty SQT in Hela cells
expressing these peptide aptamers (Figure 4c). SQT is
expressed at high levels in the cells and displays a diffuse
staining pattern, distributed evenly across all cellular com-
partments. PepPuma and pepBim show increased localisa-
tion to areas rich in mitochondria, especially surrounding the
nucleus, however, staining remains rather diffuse and
exhibits variability across different cells. These observations
are consistent with the fact that pepBim/Puma lack the
C-terminal hydrophobic domains of the full-length proteins,
which have previously been shown to be essential for
mitochondrial localisation.28,29 We conclude that the BH3
helix is sufficient for induction of apoptosis even in the
absence of a mitochondrial-targeting sequence.
In order to verify that the BH3 presenting peptide aptamers
cause programmed cell death via initiation of cytochrome c
release from the mitochondrion, a Hela cell line, which stably
expresses a green fluorescent protein (GFP)–cytochrome c
fusion protein, was used (Figure 5). In a healthy cell,
the mitochondria are visible as distinct features under
the confocal microscope (Figure 5a). Upon expression of
pepPuma, cytochrome c is released efficiently starting in
some cells from 30 to 60min following induction. Visually this
can be registered by the dissolution of the distinct mitochon-
drial illumination pattern, which leads to a diffuse staining in
the cytoplasm of these cells (Figures 5a and b).
PepNoxa and pepBad do not individually induce
apoptosis. Expression of pepNoxa or pepBad did not lead
to cleavage of PARP in A375 cells (Figure 3), indicating that
apoptosis was not induced by these anchored BH3 helices. A
similar observation has been made with the full-length
proteins, and was explained by the fact that Noxa and Bad
neutralise only a subset of anti-apoptotic Bcl-2 proteins.12 To
test pepNoxa’s apoptotic potential, a U266 myeloma cell line
was used, whose survival is dependent on Mcl-1.30 However,
expression of pepNoxa in this cell line was not sufficient to
drive apoptosis, as viability was unaffected and PARP was not
cleaved (Figure 6a). It has previously been shown that the
full-length Noxa protein possesses a C-terminal mitochondrial-
targeting domain, whose presence is required for induction of
apoptosis.31 In order to test whether targeting pepNoxa to the
mitochondrion might result in induction of cell death, Bim’s
membrane-targeting domain (Bim hydrophobic region, BHR)32
was introduced into the C-terminus of pepNoxa. Expression of
the pepNoxa-BHR protein in U266 cells led to a clear
reduction in cell numbers compared with SQT or pepNoxa
alone (Figure 6a). Fluorescent microscopy in Hela cells
confirmed that pepNoxa-BHR localises to the mitochondria,
in contrast to pepNoxa, which exhibits a diffuse staining
pattern (Figure 6b). Co-IP using an anti-Stefin A antibody to
capture pepNoxa revealed that inclusion of the BHR
significantly increases the formation of the pepNoxa:Mcl-1
complex (Figure 6c). Finally, as pepBad is predicted to mimic
the effects of the chemical Bcl-2 inhibitor ABT-737 and
synergise with the proteasomal inhibitor MG-132,33 the ability
of pepBad to promote apoptosis in A375 cells treated with
MG-132 was tested (Figure 6d). The strongest effect was
measured at a concentration of 100nM of MG-132, where
expression of pepBad leads to approximately 50% reduced
cell viability compared with the empty SQT scaffold. As with
full-length Bad, which has no known membrane-targeting
sequence, pepBad’s localisation pattern in Hela cells is
diffused (Figure 6b).
Discussion
The study of BH3 helices has value in basic research to help
further elucidate the role of these domains in apoptosis and
the regulation of mitochondrial fission, and in translational
research to inform drug design. However, in some cases the
BH3 helix alone is not sufficient to mediate biological function,
Figure 3 PARP cleavage in A375 cells expressing pepBH3 proteins. (a)
PepBim/Puma expression results in cleavage of PARP. (b) Cleavage of PARP
occurs as early as 30 min after PepBim/Puma expression is initiated and
downregulation of anti-apoptotic proteins starts after 2–4 h
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and further tools are required. Here the use of the SQT
peptide aptamer scaffold to present BH3 peptides has been
successfully validated.
At endogenous levels Bcl-2 does not interact with the
BH3-only proteins. The binding of the BH3 helices
to members of the Bcl-2 family has been thoroughly
investigated over the past 10 years. Chen et al.12 have
systematically tested the binding of several BH3 peptides to
the five anti-apoptotic Bcl-2 proteins in vitro, as well as the
interaction between full-length BH3-only proteins and a
subset of the anti-apoptotic proteins following their
overexpression in cells. Their findings match our observa-
tions to a large extent, with Puma and Bim binding to both
endogenous Bcl-xL and Mcl-1 and Bad binding strongly to
Bcl-xL but not Mcl-1 whereas Noxa was selective for Mcl-1.
Interestingly, however, endogenous Bcl-2 did not co-IP
with any of the pepBH3 (in A375 or Hela cells), or with
endogenous, full-length Bad (in A375 or 293T cells). In the
scientific literature there are, to our knowledge, only a few
instances of endogenous Bcl-2 co-IP, and in those studies
the cell types used are almost exclusively either mature34
or immature T cells14,35 or B cells;36 all cell types which
were not investigated in this study. The vast bulk of the
Figure 4 Cell viability and localisation of pepPuma/Bim in cells. (a) PepPuma/Bim expression in A375 cells reduces cell viability by approximately 80%. The western blot
shows levels of SQT with increasing amounts of Shield (error bars are ±S.D.; n¼ 3). (b) PepPumaDel does not cause cell death (error bars are ±S.D.; n¼ 3).
(c) Immunofluorescence of Hela cells expressing SQT reveals no specific localisation pattern. PepBim or pepPuma (green) colocalise with mitotracker (red) in some but not all
cells. DAPI-stained nuclei are shown in blue
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literature has only reported positive BH3:Bcl-2 inter-
actions in vitro8,12,37 or with overexpressed Bcl-2 inside
cells.12,27,38,39 The latter observation could be successfully
reproduced in this study. Notable in this context is the fact
that several haematological malignancies are driven by
translocation of the bcl-2 gene and consequent overexpres-
sion of the protein.40 Furthermore, there is some evidence
that Bcl-2 is a much weaker pro-survival factor than, for
instance, Bcl-xL41 and work with mouse embryonic fibro-
blasts has revealed that sequestration of Bcl-xL and Mcl-1 is
sufficient to induce apoptosis.42 Thus, we hypothesise that,
in most cell types, Bcl-2 might only be a relevant anti-
apoptotic player and BH3-only protein inhibitor in the over-
expressed state. Evidence corroborating our findings comes
from Deng et al.36 who tested Bcl-2:Bim interaction via IP in
18 different diffuse large B-cell lymphoma cell lines.
Importantly, they find that significant Bcl-2:Bim complex
formation is generally only detectable in those cell lines
carrying the t(14;18) translocation, where Bcl-2 levels are
high. Recently, Plo¨tz et al.43 co-IP BimL with endogenous
Bcl-2 in Mel-2a melanoma cells, a cell line known
to overexpress Bcl-2, particularly compared with A375, the
melanoma cell line used in this study.44
Only the anchored Bim BH3 helix interacts with Bax in
A375 cells. The interaction of the BH3-only proteins with the
anti-apoptotic Bcl-2 members serves to antagonise their
function. There is, however, mounting evidence that Bax and
Bak are directly activated by some of the BH3-only
proteins.15,16 In this study, only the anchored Bim a-helix
was found to bind to Bax in cells. This observation is
consistent with that by Me´rino et al.35 who report binding of
Bax to the Bim isoform BimS. Replacement of the Bim BH3
peptide within the Bim backbone with that of Bad, Noxa or
Puma led to no interaction. A different study, investigating
binding to both Bax and Bak, found that BimS IP with Bax but
found no interaction between Bak and the BH3-only proteins,
consistent with our results.45 Both studies have also looked at
the binding affinity between Bax and the Bim BH3 peptide
biophysically, and only low (mM) affinities were measured.
Here we show that an anchored Bim BH3 peptide is sufficient
to interact with Bax in cells. The efficiency of the co-IP, which
is comparable to that of pepBim and Bcl-xL, suggests that the
interaction in vivo is robust. Furthermore, Puma has previously
been shown to promote oligomerisation and activation of Bax
and Bak followed by cytochrome c release in isolated
mitochondria17 and a bacterial two-hybrid assay has identified
Puma as well as its BH3 peptide alone as interactors of Bax.46
In this study, however, no binding of the constrained Puma
helix to either Bax or Bak was detected. Others using IP
assays have also found that full-length Puma does not bind to
the pro-apoptotic effector proteins in lysed cells.45
The BH3 domain of Puma and Bim is sufficient to
induce apoptosis; a membrane-targeting sequence is
not required. One of the advantages of the anchored
peptide system described here is that it allows the study of
the BH3 peptides in a neutral and structurally stable scaffold
outside the context of their native proteins. Previously,
Weber et al.29 have shown that a truncated BimS lacking
the C-terminal hydrophobic region was incapable of localis-
ing to the mitochondria and could not induce apoptosis.
Equally a truncated Puma, with an intact BH3 domain but no
C-terminus failed to target the mitochondria and kill cells.28
Figure 5 PepPuma expression results in cytochrome c release from the mitochondria. (a) Shown are three time points in the process of apoptosis. In the left-hand panel,
both cells in the main field of view have their mitochondria intact. In the central panel, the right-hand cell is starting to undergo apoptosis with mitochondrial membrane
permeabilisation leading to the GFP signal becoming more diffuse. In the right-hand panel, the right-hand cell has completely lost mitochondrial integrity and GFP–cytochrome
c has translocated to the nucleus. (b) White arrows indicate cells before (left panel) and after (right panel) mitochondrial permeabilisation
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Here we show that the anchored BH3 helices of both Puma
and Bim exhibit a strong apoptotic effect in A375 cells.
In Hela cells, pepPuma powerfully induces cytochrome
c release (pepBim was not tested). Although pepBim and
pepPuma localise only poorly to the mitochondria, probably
because the hydrophobic C-terminus is not present, these
proteins do show increased accumulation around mitochon-
dria compared with SQT alone. These findings thus prove
that the Puma/Bim BH3 helix alone is enough to cause
apoptosis even in the absence of efficient membrane
targeting. In support of these results, several studies have
successfully induced apoptosis in cancer cells by using a
cell-permeable stapled BH3 peptides.16,47 Furthermore,
previous studies have shown that the Bim helix colocalises
well – but not perfectly – with mitochondria,47 and that,
following transfection of the Bim BH3 peptide into HeLa cells,
cytochrome c release was observed in most cells.11
A further interesting observation reported here is that the
levels of anti-apoptotic proteins fall approximately 2–4 h after
induction of pepBim or pepPuma expression. The ability of the
BH3-only proteins to regulate the stability of Mcl-1 has been
investigated before, and targeting of the death antagonists
to the proteasome by the pepBH3 proteins constitutes a
potential explanation for these findings.42,48
Noxa requires a membrane-targeting domain to induce
apoptosis; Bad does not. Contrary to Bim and Puma,
which do not require their C-terminal hydrophobic region to
cause cell death, the results obtained here show that Noxa
has to be targeted to intracellular membranes to do so.
The successful use of the BHR to target pepNoxa to the
mitochondria, instead of Noxa’s own mitochondrial-targeting
domain,31 shows that, to induce cell death, Noxa does not
require a specific targeting sequence, but simply needs to
localise to the mitochondria. This has potential implications
for the design of Mcl-1 (Noxa’s target) inhibitors to
treat malignancies such as chronic lymphocytic leukaemia
and multiple myeloma, which have been shown to be
dependent on Mcl-1 for survival.49,50 PepBad, on the other
hand, showed apoptotic potential in the absence of a
membrane-targeting domain consistent with the fact that
the natural full-length protein lacks such a feature.51
Consequently, the results support the idea that the potency
of the BH3-only Bcl-2 proteins is not only determined by their
affinity for the anti-apoptotic proteins, but is also regulated by
their intracellular localisation.
Conclusion. The anchored helix approach to studying the
BH3 peptides constitutes a way of informing the growing
Figure 6 Apoptotic potential and cellular localisation of pepNoxa and pepBad. (a) Expression of pepNoxa in U266 cells has no effect on cell viability and does not cause
PARP cleavage. PepNoxa with the BHR domain efficiently induces cell death and leads to PARP cleavage (error bars are±S.D.; n¼ 3). The inducible expression system is
leaky in this cell type and thus pepNoxa-BHR expression occurs even in the absence of shield. The set of columns labelled ‘U266’ denotes viability measurements of
untransfected cells (which are not 100% viable). PepBH3 degradation products are indicated by an asterisk (*). (b) Immunofluorescence analysis of Hela cells expressing
pepNoxa or pepBad (green) reveals no mitochondrial (red) localisation. PepNoxa-BHR colocalises very specifically with mitotracker (red). (c) Co-IP experiment using an
anti-Stefin A antibody and lysate from cells expressing pepNoxa or pepNoxa-BHR. PepNoxa-BHR is expressed at lower levels, but purifies with a larger amount of Mcl-1 than
pepNoxa lacking a BHR. (d) PepBad and MG-132 synergise to reduce viability in A375 cells (most prominently at 100 nM MG-132; error bars are±S.D.; n¼ 3)
The apoptotic functions of anchored BH3 peptides
LKJ Stadler et al
7
Cell Death and Disease
field of potential therapeutics that are the BH3 helix
mimetics18,19,52–54 and stapled helices,37,55,56 as it presents
a neutral and robust platform to study the intracellular effects
of the BH3 domains outside the context of the native protein
backbone. Other methods, such as using BimS as a common
backbone to study the BH3 helices by replacing the Bim BH3
sequence with that of the BH3-only protein to be studied
have been used successfully in the past.12,35 This approach,
however, might not always reflect the true character of
the BH3 domain under investigation as the BHR targets the
protein to intracellular membranes very efficiently. Another
important finding reported here is the apparent inability of
Bcl-2 to interact with the pro-apoptotic BH3-only proteins,
when the former is only present at endogenous levels in the
cell. Conversely, when overexpressed, binding occurs read-
ily. This suggests that Bcl-2’s role in counteracting apoptosis
might only be significant in specific pathological situations
where the protein’s expression levels are unnaturally high
(e.g., following genetic translocation). Future studies should
prioritise the verification of this hypothesis.
Materials and Methods
DNA manipulation and cloning. Double-stranded DNA cassettes
encoding each BH3 peptide (Figure 1a) or the BHR flanked by the AvrII or XhoI
restriction enzyme site, respectively, were made by annealing oligonucleotides
(Supplementary Table S1). For bacterial expression, restriction enzyme digested
dsDNA cassettes were ligated into the appropriate restriction sites of the SQT
scaffold-encoding ORF in pET30a(þ ).23 For viral transfection, each construct was
amplified by polymerase chain reaction (PCR) from pET30a(þ ) using SQT-specific
primers (F 50-CCGCGGCCGCAGATCTTCATGATACCTAGG-30, R 50-GAGAGGG
GCGCCATGCTAAAAGCCCGTCAGCTCG-30). PCR products were cloned into the
Retro-X ProteoTuner vector using In-Fusion cloning and sequenced, as per
manufacturer’s instructions (Clontech, St-Germain-en-Laye, France).
PepBH3 expression in E. coli and purification. pET30a(þ )
expression vectors containing the pepBH3 ORF were transformed into BL21
(DE3) pLysS competent cells (Stratagene, Santa Clara, CA, USA) and expressed
under induction with IPTG for 3 h at 37 1C. Cells were harvested, lysed using a
sonicator, and the recombinant protein purified using Ni-NTA sepharose beads
(Novagen, Billerica, MA, USA), as described previously.57
Production of retrovirus and transduction of cells. Constructs were
transfected into Phoenix A packaging cells (ATCC, Manassas, VA, USA), using
siPORT XP-1 transfection agent (Life Technologies, Carlsbad, CA, USA). After
48 h, the medium was harvested, 0.4mm filtered and mixed in equal amounts
with fresh medium containing 8mg/ml of polybrene (Sigma, Gillingham, UK). Cells
were incubated with retroviral supernatants for 8 h. At 48 h after transduction,
cells were transferred into selection medium containing puromycin.
Transient transfection of A375 cells. A pCMV-Tag2B vector carrying
Bcl-2 with an N-terminal Flag-tag was ordered from Addgene (Cambridge, MA, USA).
The transfection mix was assembled as follows: 3.3mg of high-quality plasmid DNA
(midiprep) per six-well plate well is diluted in sterile water to a concentration of
20 ng/ml. Then FuGeneHD transfection reagent (Promega, Southampton UK), which
has been warmed to room temperature (RT), is added directly to the solution at
10ml/3.3mg DNA. This is followed by brief vortexing and incubation at RT for
5–10 min. The mix is then added to cells, which are approximately 80% confluent, and
are grown in complete DMEM GlutaMAX medium (Life Technologies, Paisley, UK),
with 3 ml of the medium per six-well plate well. The transfected cells were harvested
after 24 h for downstream applications.
Far-UV CD spectroscopy. CD spectra were measured on a Jasco J715
spectropolarimeter (Jasco, Easton, MD, USA) as described previously.57 Briefly,
pepBH3 proteins were transferred into 50 mM sodium phosphate buffer (pH 7.4)
and their CD spectra recorded from 200 to 260 nm. The spectrum for buffer alone
was substracted from the measurements and the data analysed and visualised
using Microsoft Excel.
IP experiments. IP experiments were carried out using the Crosslinking
Immunoprecipitation kit (Pierce, Rockford, IL, USA) according to the manufac-
turer’s instructions. Briefly, cells expressing the desired protein were lysed using
the kit’s IP lysis/wash buffer (containing a non-ionic detergent) and the soluble
fraction applied to agarose beads carrying the appropriate antibody (a-Bad,
Abcam (Cambridge, UK); a-Stefin A, R&D Systems (Minneapolis, MN, USA);
a-Flag-Tag, Sigma). Lysates were incubated overnight at 4 1C and the beads were
then washed four times and eluted with a low-pH buffer. Elution fractions were
stored at  80 1C until analysis by western blotting.
Western blotting. Western blotting was preceded by sodium dodecyl
sulphate polyacrylamide gel electrophoresis and transfer onto nitrocellulose or
PVDF membrane. The membrane was blocked in 3% milk for 1 h at RT followed
by incubation with antibody at 4 1C overnight. Antibodies used were a-Stefin A
(1 : 3000; R&D Systems), a-tubulin (1 : 10 000; AbD Serotec, Kidlington, UK),
as-Mcl-1, a-Bcl-2, a-Bcl-xL, a-Bad, a-Bak and a-Bax (all 1 : 1000; all from Cell
Signalling Technology, Hitchin, UK) and a-PARP (1 : 1000; BD Biosciences,
Oxford, UK). HRP-conjugated secondary antibodies were a-mouse, a-rabbit,
a-goat (all 1 : 12 000; all from Jackson Immunoresearch, West Grove, PA, USA)
and were applied for 1 h at RT. For detection, the membrane was incubated with
ECL reagent (Pierce) and exposed to photographic film.
Immunocytochemistry. For ICC, Hela cells were cultured on glass cover
slips. Mitotracker red CMXRos (25 nM; Life Technologies, Carlsbad, CA, USA)
was added to the culture medium 30 min before fixing in 4% paraformaldehyde.
Cells were permeabilised in 2% Triton-X100 for 5 min, washed in PBS and blocked
in 2% milk for 30 min. Subsequently, the anti-Stefin A antibody was applied
(1 : 100; R&D Systems) for 2 h at RT followed by incubation with Alexa Fluor 488
labelled secondary antibody (1 : 200; Life Technologies, Carlsbad, CA, USA) and
4’,6-diamidino-2-phenylindole (DAPI) for 1 h. Before fluorescent microscopy, the
cover slips were mounted onto glass slides using ProLong Gold antifade reagent
(Life Technologies, Carlsbad, CA, USA).
Monitoring cell viability and cytochrome c release. Viability and
apoptosis assays were performed using the Guava EasyCyte System (Millipore,
Billerica, MA, USA), according to the manufacturer’s instructions. Hela cells, which
stably express GFP–cytochrome c (a kind gift from Douglas Green, St. Jude
Children’s Research Hospital, Memphis, TN, USA), were transfected with
pepPuma as described above. One hour after addition of Shield, the cells were
monitored under green fluorescence and micrographs taken every 5 min for 2 h.
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